Evidence map›Paper›PMID 40636441›Full record

ArticleNeurotrauma reports2025

Exploring the Impact of Mitoquinone Supplementation on Glycan Profiles in a Repeated Mild Traumatic Brain Injury Mouse Model.

Mona Goli, Akeem Sanni, Sakshi Gautam, Khalil Mallah, W Brad Hubbard, Mohammad Reslan, Muhammad Ali Haidar, Karim Halabi, Joseph Walker, Stefania Mondello and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotrauma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mona GoliDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.
Akeem SanniDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.
Sakshi GautamDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.
Khalil MallahDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.
W Brad HubbardDepartment of Physiology, Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky, USA.ORCID https://orcid.org/0000-0001-7018-0148
Mohammad ReslanDepartment of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Muhammad Ali HaidarDepartment of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Karim HalabiDepartment of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Joseph WalkerDepartment of Neurobiology, Center for Neurotrauma, Multiomics & Biomarkers, Morehouse School of Medicine, Neuroscience Institute, Atlanta, Georgia, USA.
Stefania MondelloDepartment of Biomedical and Dental Sciences and Morphological Imaging, University of Messina, Messina, Italy.
Firas KobeissyDepartment of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
Yehia MechrefDepartment of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) represents a significant cause of injury-related deaths and disabilities. Repeated exposure to mechanical impact can lead to metabolic and ionic imbalance, which can cause oxidative stress and worsen the cellular dysfunction initiated by the initial mild TBI (mTBI). Currently, no FDA-approved drug targets repeated mTBI (rmTBI) and its potential sequelae. Mitoquinone (MitoQ) is a mitochondrion-targeted drug that has proven beneficial in different brain-related diseases. We have previously demonstrated the neurotherapeutic effects of MitoQ at a 30-day chronic time point in a similar rmTBI mouse model, where we observed decreased neuroinflammation, enhanced behavioral outcomes, and diminished oxidation. Recently, alterations in glycans have been shown to modulate key roles in the nervous system. Their relevance has been recognized in several neurodegenerative disorders, including TBI, which indicated injury severity and pathobiology. In this study, we aimed to assess brain glycome profiles post MitoQ treatment in experimental rmTBI using liquid chromatography-tandem mass spectrometry. Our findings indicate that there is a correlation between the HexNAc

Indexed as

glycomicsLC-MS/MSneurotraumaoxidative stressrepeated mild traumatic brain injury

Identifiers

PMID40636441
PMCPMC12237849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.